Program
Moxifloxacin
Also written as “Avelox (Moxifloxacin, BAY12-8039)”, “Moxifloxacin (Avelox, BAY12-8039)” and “moxifloxacin”.
Its studies are mostly in Cataract · Conjunctivitis, Bacterial · Otitis Media · Sinusitis · Community-Acquired Pneumonia, led by 14 companies.
Drug pageMoxifloxacin: every studyMany companies study it; this page follows only the 55 they lead. All 201 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayerits history only | 200 open or running | phase 4since Jun 26, 2007 | Nov 21, 2006 | none ahead |
| Alconits history only | 140 open or running | phase 4since Apr 4, 2006 | Apr 4, 2006 | none ahead |
| Pfizerits history only | 40 open or running | phase 1since Jul 10, 2007 | Jul 10, 2007 | none ahead |
| GlaxoSmithKlineits history only | 30 open or running | phase 1since Oct 8, 2009 | Oct 8, 2009 | none ahead |
| Da Volterra | 20 open or running | phase 1since Jun 25, 2014 | Jun 25, 2014 | none ahead |
| Laboratorios Sophia S.A de C.V.its history only | 21 open or running | phase 3since Jul 30, 2025 | Apr 9, 2024 | none ahead |
| Richmond Pharmacologyits history only | 20 open or running | phase 1since Jun 19, 2012 | Jun 19, 2012 | none ahead |
| Viatrisits history only | 20 open or running | phase 1since Sep 7, 2005 | Sep 7, 2005 | none ahead |
| Adapt Produtos Oftalmológicos Ltda.its history only | 10 open or running | phase 3since Mar 22, 2011 | Mar 22, 2011 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 10 open or running | phase 1since Dec 18, 2014 | Dec 18, 2014 | none ahead |
| Intarcia Therapeuticsits history only | 10 open or running | phase 1since Jan 1, 2016 | Jan 1, 2016 | none ahead |
| Jason Ahee, M.D.its history only | 11 open or running | phase 3since Aug 4, 2017 | Aug 4, 2017 | Oct 2030phase 3 · NCT03244072 |
| Research Insightits history only | 10 open or running | phase 4since Dec 18, 2019 | Dec 18, 2019 | none ahead |
| Richmond Research Instituteits history only | 10 open or running | phase 1since Nov 8, 2013 | Nov 8, 2013 | none ahead |
Also a collaborator on its studies: AbbVie, Parexel, Bristol-Myers Squibb, Topical Solutions and Shionogi.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Da Volterra only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 25, 2014First study: phase 1 study in HealthyFirst studyNCT02176005 · 44 enrolled · France
- Sep 19, 2016Phase 1 study in Healthy SubjectsNCT02917200 · 150 enrolled · France
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Topoisomerase IV inhibitor; Bacterial DNA gyrase inhibitor”ChEMBL 37, by rule
Studies
All 2 Da Volterra leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02917200Healthy Subjects · France | 1 | Completed | Dec 2, 2016 | 150 |
| NCT02176005Healthy · France | 1 | Completed | Oct 2014 | 44 |
How it is read
Names in the registry
- “Moxifloxacin”, 32 entries
- “Avelox (Moxifloxacin, BAY12-8039)”, 11 entries
- “Moxifloxacin (Avelox, BAY12-8039)”, 9 entries
- “moxifloxacin”, 6 entries
- “Moxidex otic solution”, 5 entries
Conditions, from the studies’ own filings
- Cataract, 6 studies
- Conjunctivitis, Bacterial, 5 studies
- Otitis Media, 4 studies
- Sinusitis, 3 studies
- Community-Acquired Pneumonia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.